A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib

Trial Profile

A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 21 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 18 Oct 2016 Status changed from planning to not yet recruiting.
    • 05 Oct 2016 According to a RedHill Biopharma media release, this trial has been initiated with enrollment expected to commence shortly after final regulatory clearance.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top